Download Ensuring quality and access for malaria diagnosis: how can it be

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
“Ensuring quality and access for malaria
diagnosis: how can it be achieved?”
Nat Rev Microbiol. 2006 Sep;4(9 Suppl):S7-20.
Amy Storfa
3/23/2007
Background
• Symptoms (fever, rigors, headache) overlap with
presentations of other febrile illnesses
• P. falciparum can often lead to coma and death; other
Plasmodium spp. cause acute severe illness but rarely fatal
• Despite microscopy, most diagnoses with subsequent
treatment made based on symptoms
• Estimates of malaria deaths estimated at ~1-2 million/y
– 350-500 million cases of malaria occur annually
• Programs developed for treatment but accurate diagnosis
not emphasized
Background
• Some countries maintain microscopy-based diagnosis
programs (e.g. India)
• BUT, microscopy largely unavailable to providers of most
patients with tropical febrile illness
• Requires organized health system, supplies, reagents, good
microscopes, maintenance, competence, ability to make
blood films
• Antigen-detecting rapid diagnostic tests (RDTs) first
introduced in early 1990s and used sparingly in malaria
endemic areas
Background
• More recently, drug resistance is increasing, necessitating
switch to artemisinin-based combination therapy (ACT),
more $
• Shift has led to upsurge in use of RDTs
• But many areas (particularly sub-Saharan Africa) still rely
on symptom-based diagnosis
Early diagnosis
• Differential diagnosis of febrile tropical illness: respiratory
tract infxn, typhus, viral illness, meningitis
• Early detection/treatment likely to occur if microscopy
services are offered within 15-20 minutes of residence
• ACT ~$1.60 per course
• RDT ~$0.55 to $1.00 each
• Overall funding for research and development
– Diagnosis receives <1%, vs 37% for drug development
Advantages:
-Improved
management of
non-malarial
disease
-Savings in drug
costs
-Improved
adherence to
therapy
Implications on health care
system
•
•
•
•
Preparation and interpretation can be poor
Requires adequate level of training, supervision
Appropriate instructions developed
Requires temperature controlled distribution and
storage facilities
• Need to be stable, simple to use, able to detect
clinically significant disease (100 parasites/uL)
• Need quality assurance and control
Bell et al. Nature Reviews Microbiology 4, S7–S20 (September 2006) | doi:10.1038/nrmicro1525
Bell et al. Nature Reviews Microbiology 4, S7–S20 (September 2006) | doi:10.1038/nrmicro1525
1. HRP2
2. pLDH
3. aldolase
P. falciparum HRP-2
pLDH
Further development/study
needed
• Field trials needed to see how tests perform in field
• WHO initiative to test accuracy and stability of RDTs
• Previous studies based on various RDT types in different
clinical and epidemiological settings are difficult to
compare
• Difficult to generate conclusive comparisons of RDT
performance
• Timing of treatment and effectiveness of therapy also
complicates comparative studies
– pLDH is rapidly cleared but HRP2 persists for weeks
Malaria Review
Malaria review
• Plasmodium: four species
–
–
–
–
P. falciparum (~45%)
P. vivax (~45%)
P. ovale (rare, <5%, limited to W. Africa)
P. malariae (<5%)
• Acquired via anopheles mosquito
Malaria review: multiple forms
• Trophozoites (=ring forms): most numerous form to see in
peripheral blood, ring like structure (<1/2 diameter of cell),
progressively enlarge and mature to…
• Schizont: multinuclear structure, appear as intraerythrocytic
collection of merozoites (each with its own nucleus)
• Gametocyte: mononuclear structure occupying >1/2 the red
cell, usually amoeboid in shape and nearly fills entire RBC
Life cycle
• Mosquitoes inject
sporozoites, divide in liver
into schizonts (containing
merozoites)
• Merozoites infect RBC
and then become
trophozoites
• Again divide into
merozoites
– Can infect more RBCs
or become gametocytes
(ingested by
mosquitoes)
Malaria review
• Infects RBCs; causes intermittent hemolysis
with paroxysmal fevers
• Fever q48 h (tertian fever): P. falciparum, P.
ovale; P. vivax
• Fever q72 h (quartan fever): P. malariae
• Examine thick (for screening) and thin (for
species identification) films
Malaria review
• Signs/symptoms
– Splenomegaly
– Periodic shaking chills (rupture of RBCs)
followed by spiking fevers (merozoites
penetrating other RBCs)
– Sweats
– Anorexia
– Joint pain
P. falciparum
• Malignant tertian fever because potentially lethal
• Must be identified
• Usually only early ring forms and gametocytes
seen
– Ring forms: may have double chromatin dots, may be
multiply infected; accole or applique forms present; less
than 1/5 size of RBC
– Gametocytes: banana shaped
• Infected red cells NOT enlarged, infects RBCs of
all stages of maturation
P. falciparum
• Acute intravascular hemolysis with
hemoglobinuria (“blackwater fever”)
• Infected RBCs have “sticky knobs” leading
to sludging, infarcts of brain, kidneys
• With no treatment, patients either die or
spontaneously resolve within one year
P. falciparum
P. vivax and P. ovale
• Benign tertian fever
• Morphologically very similar
• P. ovale very rare, confined to Western
Africa
• Both infect young RBCs and appear
enlarged and pale
• All stages seen (early and developing rings,
schizonts, gametocytes)
P. vivax and P. ovale
• Schuffner’s dots may be present
• Gametocytes are amoeboid shaped, not
banana
• Schizonts have 12-14 merozoites
P. malariae
• Associated with nephrotic syndrome
• Infects older erythrocytes, normal to small sized
RBCs
• No Schuffner’s dots
• All stages seen
• Schizonts have 6-12 merozoites, rosette pattern
• Coarse pigment may be present
• Occasional band forms (trophozoite form) seen
• Low grade cryptic infections can occur up to 40 y
P. malariae
Malaria and RBC associations
• Hemoglobin S trait (HbSA) protective
against P. falciparum
• Duffy antigens mediate attachment of P.
vivax (Duffy negative patients protected
from P. vivax)
• Glucose-6-phosphate dehydrogenase
deficiency protects against ALL
Plasmodium spp.
References
•
•
•
Bell D et al. “Ensuring quality and access for malaria diagnosis: how can it be
achieved?” Nat Rev Microbiol. 2006 Sep;4(9 Suppl):S7-20.
Jones SL. Clinical Laboratory Pearls. Lippincott Williams and Wilkins, 2001.
Mais DD. Quick Compendium of Clinical Pathology. ASCP Press, 2005.